Verrica Pharmaceuticals (NASDAQ:VRCA – Free Report) had its price target raised by Needham & Company LLC from $8.00 to $16.00 in a research note issued to investors on Tuesday morning, Benzinga reports. The firm currently has a buy rating on the stock. Separately, HC Wainwright boosted their target price on Verrica Pharmaceuticals from $13.00 to […]
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA – Get Free Report) major shareholder Perceptive Advisors Llc bought 500,000 shares of the firm’s stock in a transaction on Friday, December 15th. The stock was purchased at an average cost of $5.97 per share, for a total transaction of $2,985,000.00. Following the completion of the acquisition, the insider now owns […]
Needham & Company LLC reiterated their buy rating on shares of Verrica Pharmaceuticals (NASDAQ:VRCA – Free Report) in a report released on Thursday morning, Benzinga reports. They currently have a $10.00 price objective on the stock. A number of other research firms also recently commented on VRCA. Royal Bank of Canada raised their target price […]
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA – Free Report) – Investment analysts at Brookline Capital Management issued their Q1 2024 earnings per share estimates for Verrica Pharmaceuticals in a research note issued on Monday, June 26th. Brookline Capital Management analyst K. Dolliver anticipates that the company will earn ($0.49) per share for the quarter. The consensus estimate […]
Should You Buy or Sell Verrica Pharmaceuticals Stock? Get The Latest VRCA Stock Forecast, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.